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combined end point of CHF-related death or hospital stay for
CHF, mainly as the result of a reduced hospitalization rate. At
baseline in both groups, a similar percentage of patients received
angiotensin-converting enzyme inhibitors (ACEIs) and beta-
blockers with a comparable percentage of recommended doses. At
the end of the first 3 months, however, mean dosages of ACEIs
and beta-blockers were significantly greater in the BNP group,
which was considered to be the reason for the more favorable
outcome of the BNP group.
These results are consistent with a previous smaller study
suggesting superiority of N-terminal prohormone brain natriuretic
peptide-guided treatment to clinically guided therapy (3). Al-
though in that previous study beta-blockers were not yet generally
prescribed, patients with CHF also received markedly lower
dosages of ACEIs in the clinical group than in the BNP group.
However, in both studies, it does not appear conclusive why a
patient who got blood drawn for BNP assessment should better
tolerate up-titration of heart failure medication to target dosages.
Thus, a considerable subset of patients in the clinical group
“guided by guidelines” appears not to have been treated according
to target dosages recommended in these guidelines.
Therefore, the study by Jourdain et al. (1) indicates that, for
whatever reason, doctors are more likely to adhere to a target range
of a surrogate parameter than to evidence-based recommendations
of pharmacological doses and supports consequent up-titration to
target doses in all CHF patients independent of BNP levels. To
possibly support BNP-guided dosing, randomized trials are re-
quired assessing: 1) whether it is safe to keep patients on a
low/moderate dose of ACEIs and beta-blockers after reaching
normal BNP levels versus further up-titration to target dosages
according to guidelines; and 2) whether patients with persistent
elevated BNP levels despite target doses of ACEIs and beta-
blockers benefit from dose increases beyond current target dosages
if tolerated. In conclusion, currently available data do not yet justify
a differential therapeutic strategy guided by BNP and do not
support the superiority of BNP-guided treatment if doctors would
more consequently adhere to dose recommendations of guidelines.
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Reply
We thank Dr. Hoppe for the interest in our report (1). The
concern about the maximal treatment of the patients at baseline is
of utmost importance. In the brain natriuretic peptide (BNP)
group, mean angiotensin-converting enzyme inhibitor (ACEI)
dosage increased from 96% of recommended dosage to 106% (i.e.,
some patients [36%] finally received dosage greater than that
recommended by the European Society of Cardiology [ESC]).
Similarly, the dosage of beta-blockade was increased as 58% of the
patients received recommended dosage at baseline versus 77% after
3 months.
These figures are very high compared with those obtained in
the large studies regarding beta-blockade: 43% (2) to 65% (3)
received the target dose of beta-blockade in the COPERNICUS
(Carvedilol Prospective Randomized Cumulative Survival Study
Group), MERIT HF (Metoprolol CR/XL Randomised Intervention
Trial in Congestive Heart Failure), CIBIS (Cardiac Insufficiency
Bisoprolol Study)-II, or SENIORS (Study of Effects of Nebivolol
Intervention on Outcomes and Rehospitalization in Seniors with
heart failure) trials. These figures are obtained in studies focused on
beta-blockade, in which patient selection obviously limited the num-
ber of patients who were intolerant to beta-blockage. Besides, al-
though most patients were receiving an ACEI or an angiotensin
receptor blocker, the dosage of these drugs remains unpublished.
Finally, triple therapy is infrequent in these studies, with a rate ranging
from 20% to 28% of the patients when reported. In other words,
optimal dosages have been determined in studies during which only
one drug dosage was pushed to its maximum and, even so, tolerability
was not perfect.
Accordingly, all registries report the use of lower dosages for all
class of drugs. Even in recent randomized trials (including selected
patients) evaluating nonpharmacological therapy, “optimal ther-
apy” did not mean that all patients were receiving recommended
dosages: for example, in CARE-HF (Cardiac Resynchronization
Heart Failure Study) (4), 80% were receiving an ACEI, of whom
38% received more than 50% of recommended dosage. Similarly,
72% were receiving a beta-blocker, of whom 39% received more
than one-half the recommended dosage. In conclusion, although it
remains logical to recommend the target dose derived from
randomized trial, it is not to be expected that all patients will
tolerate all drugs at recommended dosages.
The last ESC guidelines on chronic heart failure including triple
therapy were published in 2005 (5), after the STARS-BNP
(Systolic Heart Failure Treatment Supported by BNP) study was
completed (however, 33% of the patients included received a triple
therapy at baseline). This triple therapy was recommended after
the CHARM (Candesartan in Heart Failure) trial. Further illus-
trating our point, in this study, only 55% of the patients were
receiving beta-blocker therapy (6), at an optimal dosage in an
unknown proportion. Mean dosage of ACEI was 84% of that
recommended by the ESC (vs. 96% in our study).
Therefore, there should not be confusion between recom-
mendations for prescription, which is the aim, with expected
prescription in the real life. Treatment at baseline was maximal
in the STARS-BNP study. Logically, in the BNP group,
“over-treatment” according to ESC guidelines was experienced
in some patients after 3 months.
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We agree with Dr. Hoppe that it would be interesting to know
whether the dosage of the drugs for congestive heart failure could
be decreased in a subset of patients, possibly identified using
plasma BNP measurements, but this was not the aim of the
STARS-BNP study. What the STARS-BNP study shows is that
going beyond what is thought clinically by experts to be maximal
treatment is beneficial in the group of patients with increased
plasma BNP levels. We hope this simple message will allow
improvement in patient management in the real world.
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